Cancer Prevention Program
Cancer Prevention Program
News Article | May 23, 2017
BOSTON--(BUSINESS WIRE)--Press Ganey today announced that Robin Roberts, co-anchor of ABC's "Good Morning America" and renowned newscaster will deliver the keynote address at its 2017 National Client Conference, November 1-3 in Orlando, Florida. The annual three-day event draws more than 3,000 health care professionals from across the continuum of care to share best practices, network with peers and discuss strategies to improve the overall safety, quality and experience of care. “We are honored to host Robin Roberts to share her experiences as a journalist and anchor covering breaking news events, interviews with world leaders and her courageous and public battle with breast cancer and myelodysplastic syndrome,” said Patrick T. Ryan, CEO, Press Ganey. “We look forward to this inspirational keynote from Robin as we convene caregivers at our National Client Conference to explore innovative strategies that will transform health care.” An inspiration to many, Robin Roberts has used personal challenges and triumphs to raise awareness of important issues around the world. In her memoir, Everybody’s Got Something published in April 2014, Roberts shares the amazing story of her battle against a life-threatening illness, the life lessons she continues to learn and her inspiring return to the GMA anchor desk. Under Roberts’ leadership, as co-anchor of ABC's "Good Morning America," the broadcast has won five Emmy Awards for “Outstanding Morning Program”. When not traveling around the world covering global events, Roberts is at GMA’s studio in Times Square conducting interviews with a diverse group of newsmakers. She has been acknowledged with awards and honors from organizations around the country, including The Susan G. Komen Foundation, The Congressional Families Cancer Prevention Program, and Gilda’s Club. At the 2013 ESPY Awards, Roberts was honored with the Arthur Ashe Courage Award for the strength and courage she has displayed throughout her life and career. The Press Ganey National Client Conference is the premier patient experience event designed for health care professionals dedicated to advancing the safety, quality and experience of care. The conference will be held Nov. 1-3 at the Orlando World Center Marriott Resort. For more information please visit the event website. Press Ganey is a leading provider of patient experience measurement, performance analytics and strategic advisory solutions for health care organizations across the continuum of care. Press Ganey is recognized as a pioneer and thought leader in patient experience measurement and performance improvement solutions. The company’s mission is to help health care organizations reduce patient suffering and enhance caregiver resilience to improve the safety, quality and experience of care.
News Article | March 27, 2017
There’s a whole lot more to colon cancer prevention than just colonoscopy. A key here is understanding the progression of the cancer and polyps developing before it, according to experts. An important first step here is colonoscopy, but the condition still demands a larger, more comprehensive prevention plan. Dr. Joel Levine, who co-founded the Colon Cancer Prevention Program of UConn Health, harped on the interaction of three broad areas in better understanding colon cancer. "The key is the interaction of three broad areas: insulin biology, inflammation biology, and the billions of species of bacteria in the colon, the microbiome,” he said in a UConn report. Insulin biology is anything that affects insulin levels, insulin-linked proteins, as well as insulin resistance. Such are risk factors collectively known as metabolic syndrome and cover risk factors such as obesity, diabetes, and a sedentary lifestyle. Cellular inflammation is an invisible process for the patient, and it often signals a bacterial shift in the colon. Plenty of inflammatory signaling, Levine explained, leads to damage to one’s genes, DNA, and other cellular elements. It could set the stage for more mutations, which could result in the development of colon polyps with their own specific history. Changes in one’s microbiome, composed of the billions of species in one’s gut and body, are linked to certain outcomes such as colon cancer. “Further evidence has demonstrated a relationship between specific bacteria and specific molecular pathways for colon polyps,” Levine added. Colonoscopy identifies most polyps, yet recognizes inflammation as well as bacterial changes can offer red flags before actual polyp formation. And while this detection tool is crucial, it is also deemed a must to lower a person’s risk profile in between colonoscopies. Levine said, for instance, that they have not seen a colon cancer case in patients they follow in their risk identification and reduction program in the last five years. This also takes into account the fact that under normal circumstances, there is up to a 10-year interval for polyps to form, so regular monitoring proves critical. Their center tracks molecular-level changes between colonoscopies via a form of the fecal immunochemical test, which is tasked to measure protein in blood in a stool sample in billionths of one gram. According to colorectal surgeon Dr. Jitesh Patel, colorectal cancer is around 90 percent treatable when discovered in the earliest stages. “While a colonoscopy may not be a fun experience, it could save your life,” he wrote in a commentary, highlighting this diagnostic tool is recommended for everyone starting age 50 or much younger if one is high-risk. Blacks, for one, should be screened at 45 years old or younger. The American Cancer Society noted that colorectal cancer emerges as the third leading cause of death related to cancer in the United States. But while it generally affects people in their 50s, a new report warned that colon and rectal cancers are on the rise among young adults. And the condition has “very, very subtle” signs and symptoms, earning it the title of being an invisible disease. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.
Brasky T.M.,Ohio State University |
Darke A.K.,Statistical Center |
Song X.,Cancer Prevention Program |
Tangen C.M.,Statistical Center |
And 11 more authors.
Journal of the National Cancer Institute | Year: 2013
BackgroundStudies of dietary ω-3 fatty acid intake and prostate cancer risk are inconsistent; however, recent large prospective studies have found increased risk of prostate cancer among men with high blood concentrations of long-chain ω-3 polyunsaturated fatty acids ([LCω-3PUFA] 20:5ω3; 22:5ω3; 22:6ω3]. This case-cohort study examines associations between plasma phospholipid fatty acids and prostate cancer risk among participants in the Selenium and Vitamin E Cancer Prevention Trial.MethodsCase subjects were 834 men diagnosed with prostate cancer, of which 156 had high-grade cancer. The subcohort consisted of 1393 men selected randomly at baseline and from within strata frequency matched to case subjects on age and race. Proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for associations between fatty acids and prostate cancer risk overall and by grade. All statistical tests were two-sided.ResultsCompared with men in the lowest quartiles of LCω-3PUFA, men in the highest quartile had increased risks for low-grade (HR = 1.44, 95% CI = 1.08 to 1.93), high-grade (HR = 1.71, 95% CI = 1.00 to 2.94), and total prostate cancer (HR = 1.43, 95% CI = 1.09 to 1.88). Associations were similar for individual long-chain ω-3 fatty acids. Higher linoleic acid (ω-6) was associated with reduced risks of low-grade (HR = 0.75, 95% CI = 0.56 to 0.99) and total prostate cancer (HR = 0.77, 95% CI = 0.59 to 1.01); however, there was no dose response.ConclusionsThis study confirms previous reports of increased prostate cancer risk among men with high blood concentrations of LCω-3PUFA. The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis. Recommendations to increase LCω-3PUFA intake should consider its potential risks. © 2013 The Author.
Moinpour C.M.,Cancer Prevention Program |
Moinpour C.M.,University of Washington |
Darke A.K.,Fred Hutchinson Cancer Research Center |
Donaldson G.W.,University of Utah |
And 8 more authors.
Journal of the National Cancer Institute | Year: 2012
Background The Prostate Cancer Prevention Trial (PCPT)a randomized placebo-controlled study of the efficacy of finasteride in preventing prostate canceroffered the opportunity to prospectively study effects of finasteride and other covariates on the health-related quality of life of participants in a multiyear trial. MethodsWe assessed three health-related quality-of-life domains (measured with the Health Survey Short Form36: Physical Functioning, Mental Health, and Vitality scales) via questionnaires completed by PCPT participants at enrollment (3 months before randomization), at 6 months after randomization, and annually for 7 years. Covariate data obtained at enrollment from patient-completed questionnaires were included in our model. Mixed-effects model analyses and a cross-sectional presentation at three time points began at 6 months after randomization. All statistical tests were two-sided. ResultsFor the physical function outcome (n = 16 077), neither the finasteride main effect nor the finasteride interaction with time were statistically significant. The effects of finasteride on physical function were minor and accounted for less than a 1-point difference over time in Physical Functioning scores (mixed-effect estimate = 0.07, 95% confidence interval [CI] =-0.28 to 0.42, P =. 71). Comorbidities such as congestive heart failure (estimate =-5.64, 95% CI =-7.96 to-3.32, P <. 001), leg pain (estimate =-2.57, 95% CI =-3.04 to-2.10, P <. 001), and diabetes (estimate =-1.31, 95% CI =-2.04 to-0.57, P <. 001) had statistically significant negative effects on physical function, as did current smoking (estimate =-2.34, 95% CI =-2.97 to-1.71, P <. 001) and time on study (estimate =-1.20, 95% CI =-1.36 to-1.03, P <. 001). Finasteride did not have a statistically significant effect on the other two dependent variables, mental health and vitality, either in the mixed-effects analyses or in the cross-sectional analysis at any of the three time points. ConclusionFinasteride did not negatively affect SF36 Physical Functioning, Mental Health, or Vitality scores. © 2012 The Author.
PubMed | Cancer Prevention Program, Biostatistics and Biomathematics Program and., Fred Hutchinson Cancer Research Center and Cancer Prevention Program.
Type: Journal Article | Journal: The Journal of nutrition | Year: 2015
The consumption and blood concentrations of lycopene are both positively and inversely associated with the risk of several chronic diseases. The inconsistences in lycopene disease association studies may stem from a lack of knowledge about the genetic variation in the synthesis, metabolism, and deposition of transport and binding proteins, which potentially influence serum lycopene concentrations.We examined the association between variation across the genome and serum concentrations of lycopene in a multiethnic population.Participants included African (n = 914), Hispanic (n = 464), and European (n = 1203) American postmenopausal women from the Womens Health Initiative. We analyzed 7 million single nucleotide polymorphisms (SNPs). Linear regression models were used to assess associations between each SNP and serum concentrations (log transformed, continuous) of lycopene; we adjusted for age, body mass index, and population substructure. Models were run separately by ethnicity, and results were combined in a transethnic fixed-effects meta-analysis.In the meta-analysis, the scavenger receptor class B, member 1 (SCARB1) gene, which encodes for a cholesterol membrane transporter, was significantly associated with lycopene concentrations (rs1672879; P < 2.68 10(-9)). Each additional G allele resulted in a 12% decrease in lycopene concentrations for African Americans, 20% decrease for Hispanic Americans, and 9% decrease for European Americans. In addition, 2 regions were significantly associated with serum lycopene concentrations in African Americans: the slit homolog 3 gene (SLIT3), which serves as a molecular guidance cue in cellular migration, and the dehydrogenase/reductase (SDR family) member 2 (DHRS2) gene, which codes for an oxidoreductase that mitigates the breakdown of steroids.We found 3 novel loci associated with serum lycopene concentrations, 2 of which were specific to African Americans. Future functional studies looking at these specific genes may provide insight into the metabolism and underlying function of lycopene in humans, which may further elucidate lycopenes influence on disease risk and health. This trial was registered at clinicaltrials.gov as NCT00000611.